tagged with: Genentech
This is Part Two of my interview with Todd Pierce, CIO of Genentech. In Part One, we spoke about effective communication.
The holy grail of post-recession business will be profitable growth. The very idea of profitable growth is full of contradiction, as growth generally requires investment. With revenues unlikely to outpace that investment in what economists are predicting will be an anemic, drawn-out recovery, companies that have already been doing a lot of cost cutting will have to become even more efficient. This will put unusual pressure on executives to place the right bets when it comes to investments (based on strong customer insight and market knowledge). And it will require excellent management abilities and flexible, responsive, lower-cost IT.
Great communicators focus on the perspectives, priorities and frames of reference of the people they seek to communicate with. At Genentech, that means science. Todd Pierce, SVP and CIO at Genentech, views effective communication as the “circulatory system" of business. Everything he does takes that into account.
Being in the drug discovery/drug development business, Genentech runs on quickly gathering large volumes of information and analyzing it effectively. With 30-40 clinical trials going on at any given time, that's a lot of information.